Business Context and Reporting Period
This Form 8-K was filed by SeaStar Medical Holding Corporation on December 27, 2023. The report addresses a critical corporate governance and listing status issue regarding the company's common stock (trading symbol: ICU) on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
- Failure to Regain Compliance: The company failed to meet the Nasdaq Listing Rule 5550(b)(1) requirement, which mandates a minimum bid price of $1.00 per share for 30 consecutive business days.
- Delisting Notice: On December 27, 2023, the Nasdaq Listing Qualifications Department issued a formal Delisting Notice confirming the company did not regain compliance by the December 27, 2023 deadline.
- Continued Trading: Despite the notice, the company's stock will continue to trade on The Nasdaq Capital Market pending the final decision of the Nasdaq Hearings Panel.
Outlook, Risks, and Management Commentary
- Upcoming Hearing: The Nasdaq Hearings Panel is scheduled to consider the matter on March 12, 2024. The company intends to present its views at this hearing.
- Delisting Risk: If the company fails to address the deficiency at the hearing, the Panel may determine to delist the stock based on the record presented.
- Immediate Impact: The filing states that neither the Delisting Notice nor the noncompliance will have an immediate effect on the listing or trading of the common stock.
Investor Verification Checklist
- Verify the current bid price of ICU stock to assess the severity of the pricing deficiency.
- Monitor the outcome of the Nasdaq Hearings Panel scheduled for March 12, 2024.
- Review the company's plan to regain compliance, such as a reverse stock split or other capital structure changes, if disclosed in subsequent filings.
- Check for any additional 8-K filings regarding the hearing results or potential transfer to the OTC markets.